# Distinct T cell subsets associated with responses to different neoadjuvant treatments in esophageal squamous cell carcinoma

Source: [cell.com](https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(26)00579-3?rss=yes) · 2026-11-11 · Medicine
Page: https://themorning.science/story/distinct-t-cell-subsets-associated-with-responses-to-different-neoadjuvant-treat-79289212e7d56c45
Kind: research · Impact: medium

## In brief

- Study by Song et al. compares T cell subsets in esophageal squamous cell carcinoma under two neoadjuvant treatments.
- Neoadjuvant immunochemotherapy maintains immunoresponsive CXCL13+ CD8+ T cells, per the source.
- Chemoradiotherapy reduces the CXCL13+ CD8+ T cell compartment and enriches PD-1- effector CD8+ T cells, per the source.

## Why it matters

The findings link specific T cell populations to treatment response, which may help explain why patients respond differently to immunochemotherapy versus chemoradiotherapy in esophageal cancer.

## Timeline

- 2026-11-11: Study published in Cell Reports Medicine

## Coverage

- [Distinct T cell subsets associated with responses to different neoadjuvant treatments in esophageal squamous cell carcinoma](https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(26)00579-3?rss=yes) — cell.com, 2026-11-11

Tags: esophageal cancer, t cells, immunotherapy, neoadjuvant therapy, tumor immunology

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science